FNY Investment Advisers LLC Increases Stock Position in The Chemours Company $CC

FNY Investment Advisers LLC boosted its stake in shares of The Chemours Company (NYSE:CC) by 100.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,000 shares of the specialty chemicals company’s stock after buying an additional 2,000 shares during the quarter. FNY Investment Advisers LLC’s holdings in Chemours were worth $45,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of CC. Millennium Management LLC boosted its stake in Chemours by 60.4% during the first quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company’s stock worth $54,428,000 after buying an additional 1,515,520 shares during the period. Vanguard Group Inc. boosted its stake in Chemours by 8.3% during the first quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company’s stock worth $223,069,000 after buying an additional 1,263,047 shares during the period. Public Sector Pension Investment Board purchased a new position in Chemours during the first quarter worth about $6,411,000. Principal Financial Group Inc. boosted its stake in Chemours by 116.3% during the first quarter. Principal Financial Group Inc. now owns 742,119 shares of the specialty chemicals company’s stock worth $10,041,000 after buying an additional 399,097 shares during the period. Finally, Nuveen LLC purchased a new position in Chemours during the first quarter worth about $4,132,000. Hedge funds and other institutional investors own 76.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on CC shares. Zacks Research lowered shares of Chemours from a “hold” rating to a “strong sell” rating in a research note on Friday, October 17th. Mizuho lowered their price objective on shares of Chemours from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Thursday, October 16th. Truist Financial raised their price objective on shares of Chemours from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 16th. Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a research note on Wednesday, October 8th. Finally, UBS Group raised their price objective on shares of Chemours from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $18.50.

Insiders Place Their Bets

In other news, CEO Denise Dignam bought 4,068 shares of Chemours stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average price of $12.06 per share, with a total value of $49,060.08. Following the completion of the acquisition, the chief executive officer directly owned 191,546 shares in the company, valued at $2,310,044.76. The trade was a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.47% of the stock is currently owned by company insiders.

Chemours Trading Up 2.5%

NYSE CC opened at $13.86 on Friday. The firm has a 50 day simple moving average of $15.31 and a 200-day simple moving average of $13.06. The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68. The Chemours Company has a one year low of $9.13 and a one year high of $22.38. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -4.95 and a beta of 1.65.

Chemours (NYSE:CC) last issued its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.12. The firm had revenue of $1.62 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.38 earnings per share. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 15th were issued a $0.0875 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.35 annualized dividend and a yield of 2.5%. Chemours’s dividend payout ratio (DPR) is -12.50%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.